However, compared to de novo disease, RUNX1 mutations might also have different clinical consequences in MDS and sAML [19, 20], as these diseases comprise higher rates of additional mutations such as ASXL1, TET2, and EZH2 [21], leading to the classification of sAML as a separate biological entity by several researchers [22]. The gene discussed is RUNX1; the disease is myelodysplastic syndrome.